470 related articles for article (PubMed ID: 33967771)
1. Prevalence of Chemotherapy-Induced Peripheral Neuropathy in Multiple Myeloma Patients and its Impact on Quality of Life: A Single Center Cross-Sectional Study.
Selvy M; Kerckhove N; Pereira B; Barreau F; Nguyen D; Busserolles J; Giraudet F; Cabrespine A; Chaleteix C; Soubrier M; Bay JO; Lemal R; Balayssac D
Front Pharmacol; 2021; 12():637593. PubMed ID: 33967771
[TBL] [Abstract][Full Text] [Related]
2. Motor disorders related to oxaliplatin-induced peripheral neuropathy: long-term severity and impact on quality of life.
Balayssac D; Kerckhove N; Selvy M; Pereira B; Gonneau C; Pétorin C; Vimal-Baguet A; Melnikov S; Kullab S; Hebbar M; Bouché O; Slimano F; Bourgeois V; Lebrun-Ly V; Thuillier F; Mazard T; Tavan D; Benmammar KE; Monange B; Ramdani M; Péré-Vergé D; Huet-Penz F; Bedjaoui A; Genty F; Leyronnas C; Pezet D; Martin V
Support Care Cancer; 2024 Jun; 32(7):427. PubMed ID: 38869647
[TBL] [Abstract][Full Text] [Related]
3. Relation between auditory difficulties and bortezomib-induced peripheral neuropathy in multiple myeloma: a single-center cross-sectional study.
Giraudet F; Selvy M; Kerckhove N; Pereira B; Barreau F; Nguyen D; Busserolles J; Cabrespine A; Chaleteix C; Soubrier M; Bay JO; Lemal R; Balayssac D
Eur Arch Otorhinolaryngol; 2022 Apr; 279(4):2197-2201. PubMed ID: 35098333
[TBL] [Abstract][Full Text] [Related]
4. Chemotherapy-induced neuropathy in multiple myeloma: influence on quality of life and development of a questionnaire to compose common toxicity criteria grading for use in daily clinical practice.
Beijers AJ; Vreugdenhil G; Oerlemans S; Eurelings M; Minnema MC; Eeltink CM; van de Poll-Franse LV; Mols F
Support Care Cancer; 2016 Jun; 24(6):2411-20. PubMed ID: 26634561
[TBL] [Abstract][Full Text] [Related]
5. Chemotherapy-Induced Peripheral Neuropathy and its Impact on Health-Related Quality of Life among Multiple Myeloma Patients: A Single-Center Experience.
Shaheen NA; Alqahtani M; Alawbthani NS; Thomas A; Alaskar A
Indian J Palliat Care; 2020; 26(4):506-511. PubMed ID: 33623313
[TBL] [Abstract][Full Text] [Related]
6. Long-Term Prevalence of Sensory Chemotherapy-Induced Peripheral Neuropathy for 5 Years after Adjuvant FOLFOX Chemotherapy to Treat Colorectal Cancer: A Multicenter Cross-Sectional Study.
Selvy M; Pereira B; Kerckhove N; Gonneau C; Feydel G; Pétorin C; Vimal-Baguet A; Melnikov S; Kullab S; Hebbar M; Bouché O; Slimano F; Bourgeois V; Lebrun-Ly V; Thuillier F; Mazard T; Tavan D; Benmammar KE; Monange B; Ramdani M; Péré-Vergé D; Huet-Penz F; Bedjaoui A; Genty F; Leyronnas C; Busserolles J; Trevis S; Pinon V; Pezet D; Balayssac D
J Clin Med; 2020 Jul; 9(8):. PubMed ID: 32727095
[TBL] [Abstract][Full Text] [Related]
7. The prevalence and pattern of chemotherapy-induced peripheral neuropathy among women with breast cancer receiving care in a large community oncology practice.
Simon NB; Danso MA; Alberico TA; Basch E; Bennett AV
Qual Life Res; 2017 Oct; 26(10):2763-2772. PubMed ID: 28664460
[TBL] [Abstract][Full Text] [Related]
8. Colorectal Cancer Survivors Suffering From Sensory Chemotherapy-Induced Peripheral Neuropathy Are Not a Homogenous Group: Secondary Analysis of Patients' Profiles With Oxaliplatin-Induced Peripheral Neuropathy.
Kerckhove N; Selvy M; Lambert C; Gonneau C; Feydel G; Pétorin C; Vimal-Baguet A; Melnikov S; Kullab S; Hebbar M; Bouché O; Slimano F; Bourgeois V; Lebrun-Ly V; Thuillier F; Mazard T; Tavan D; Benmammar KE; Monange B; Ramdani M; Péré-Vergé D; Huet-Penz F; Bedjaoui A; Genty F; Leyronnas C; Busserolles J; Trévis S; Pinon V; Pezet D; Balayssac D
Front Pharmacol; 2021; 12():744085. PubMed ID: 34803689
[TBL] [Abstract][Full Text] [Related]
9. Co-occurrence and metabolic biomarkers of sensory and motor subtypes of peripheral neuropathy from paclitaxel.
Chen CS; Smith EML; Stringer KA; Henry NL; Hertz DL
Breast Cancer Res Treat; 2022 Aug; 194(3):551-560. PubMed ID: 35760975
[TBL] [Abstract][Full Text] [Related]
10. Painful and non-painful chemotherapy-induced peripheral neuropathy and quality of life in colorectal cancer survivors: results from the population-based PROFILES registry.
Bonhof CS; Trompetter HR; Vreugdenhil G; van de Poll-Franse LV; Mols F
Support Care Cancer; 2020 Dec; 28(12):5933-5941. PubMed ID: 32281032
[TBL] [Abstract][Full Text] [Related]
11. Electronic versus paper-pencil methods for assessing chemotherapy-induced peripheral neuropathy.
Knoerl R; Gray E; Stricker C; Mitchell SA; Kippe K; Smith G; Dudley WN; Lavoie Smith EM
Support Care Cancer; 2017 Nov; 25(11):3437-3446. PubMed ID: 28577231
[TBL] [Abstract][Full Text] [Related]
12. Long-Term Effects, Pathophysiological Mechanisms, and Risk Factors of Chemotherapy-Induced Peripheral Neuropathies: A Comprehensive Literature Review.
Kerckhove N; Collin A; Condé S; Chaleteix C; Pezet D; Balayssac D
Front Pharmacol; 2017; 8():86. PubMed ID: 28286483
[TBL] [Abstract][Full Text] [Related]
13. Duloxetine prevents bortezomib and paclitaxel large-fiber chemotherapy-induced peripheral neuropathy (LF-CIPN) in sprague dawley rats.
Mansooralavi N; Khomula EV; Levine JD
Mol Pain; 2023; 19():17448069231185694. PubMed ID: 37338165
[TBL] [Abstract][Full Text] [Related]
14. Chemotherapy-Induced Peripheral Neuropathy Impacts Quality Of Life And Activities Of Daily Living Of Brazilian Multiple Myeloma Patients.
de Miranda Drummond PL; Dos Santos RMM; Silveira LP; Malta JS; Reis AMM; Costa NL; de Paula E Silva RO; Fagundes EM; de Pádua CAM
Curr Drug Saf; 2023 Aug; ():. PubMed ID: 37592770
[TBL] [Abstract][Full Text] [Related]
15. Impact of Chemotherapy-Induced Peripheral Neuropathy on Quality of Life in Patients with Advanced Lung Cancer Receiving Platinum-Based Chemotherapy.
Hung HW; Liu CY; Chen HF; Chang CC; Chen SC
Int J Environ Res Public Health; 2021 May; 18(11):. PubMed ID: 34073174
[TBL] [Abstract][Full Text] [Related]
16. Role of pattern recognition receptors in chemotherapy-induced neuropathic pain.
Araldi D; Khomula EV; Bonet IJM; Bogen O; Green PG; Levine JD
Brain; 2024 Mar; 147(3):1025-1042. PubMed ID: 37787114
[TBL] [Abstract][Full Text] [Related]
17. Anxiety and depression mediate the association between chemotherapy-induced peripheral neuropathy and fatigue: Results from the population-based PROFILES registry.
Bonhof CS; van de Poll-Franse LV; Vissers PAJ; Wasowicz DK; Wegdam JA; Révész D; Vreugdenhil G; Mols F
Psychooncology; 2019 Sep; 28(9):1926-1933. PubMed ID: 31293046
[TBL] [Abstract][Full Text] [Related]
18. Measurement properties of brief neuropathy screening items in cancer patients receiving taxanes, platinums, or proteasome inhibitors.
Knoerl R; Mazzola E; Mitchell SA; Hong F; Salehi E; McCleary N; Ligibel JA; Reyes K; Berry DL
J Patient Rep Outcomes; 2021 Sep; 5(1):101. PubMed ID: 34568984
[TBL] [Abstract][Full Text] [Related]
19. Neuropathic Pain and Nerve Growth Factor in Chemotherapy-Induced Peripheral Neuropathy: Prospective Clinical-Pathological Study.
Velasco R; Navarro X; Gil-Gil M; Herrando-Grabulosa M; Calls A; Bruna J
J Pain Symptom Manage; 2017 Dec; 54(6):815-825. PubMed ID: 28797868
[TBL] [Abstract][Full Text] [Related]
20. Assessing patient-reported peripheral neuropathy: the reliability and validity of the European Organization for Research and Treatment of Cancer QLQ-CIPN20 Questionnaire.
Lavoie Smith EM; Barton DL; Qin R; Steen PD; Aaronson NK; Loprinzi CL
Qual Life Res; 2013 Dec; 22(10):2787-99. PubMed ID: 23543373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
